Postmastectomy radiotherapy  by Korzeniowski, Stanisław
Korzeniowski: Postmastectomy radiotherapy. 
Rep. Pract. Oncol. Radiother. 7 (1) 2002 
POSTMASTECTOMY RADIOTHERAPY 
 
Stanisław Korzeniowski 
 
Department of Radiation Oncology, Centre of Oncology- Maria Skłodowska- Curie Memorial Institute, 
Kraków, Poland 
 
Received September 27th, 2001; received in a revised form January 17th, 2002; accepted February 1st, 
2002 
 
INTRODUCTION  
 
   The value of postmastectomy radiothe-
rapy (PMRT) has been the subject of long 
lasting controversy. The results of early 
clinical trials and retrospective analyses 
have shown that irradiation is highly 
effective in reducing the incidence of loco-
regional recurrences but does not increase 
relapse-free and overall survival. However, 
the results of randomized trials published 
recently strongly indicate that PMRT 
improves both relapse-free and overall 
survival in node positive patients treated 
with mastectomy and adjuvant systemic 
therapies. This conclusion is mainly based 
on the results of the Danish Breast Cancer 
Cooperative Group (DBCG) Trials 82b and 
82c, which are summarized in Table 1 
[1,2]. In breast cancer patients the main 
cause of deaths are distant metastases, 
and any treatment which improves survival 
should reduce the risk of dissemination. 
The mechanism by which PMRT reduces 
this risk is the prevention of dissemination 
from subclinical disease which remains 
after mastectomy within the scar/chest 
wall and regional lymph nodes and which 
is poorly controlled by adjuvant systemic 
therapy. To demonstrate the existence 
of the above mechanism one should 
compare the cumulative risk of distant 
metastases in patients treated with and 
without radiotherapy. In the Danish trials 
such data are not available because it was 
only the first site of failure that was scored. 
In Table 2, results of the British Columbia 
Cancer Agency (BCCA) and Stockholm I 
trials are presented. They show a signi-
ficant reduction in the incidence of distant 
metastases in irradiated patients in com-
parison with the control groups treated 
with mastectomy alone (Stockholm) 
or with mastectomy and adjuvant CMF 
(BCCA) [3,4]. 
 
Table 1. Results of DBCG 82b and 82c randomized trials.  
 
Endpoint (10 year) Study/treatment Number of patients % LCR relapse %RFS %OS 
DBCG 82b: 
      CMF 
      CMF+RT  
 
856 
852 
 
32 
9      
 p<0.001 
 
34 
48   
 p<0.001 
 
45 
54     
p<0.001 
DBCG 82C 
       TAM 
       TAM+RT 
 
689 
686 
 
35 
10   
p<0.001 
 
24 
35   
 p<0.001 
 
36 
45    
 p< 0.03 
Table 2. Results of Stockholm I and BCCA randomized trials. 
 
Endpoint ( 15 years). Study/treatment Number of patients % LCR relapse % distant metastases % RFS % OS. 
Stockholm I: 
Surgery 
Surgery+RT 
 
120 
118 
 
 
56 
19 
p<0.0001 
 
72 
54 
p<0.01 
 
18 
33 
p<0.001 
 
30 
39 
p=0.20 
BCCA 
      CMF 
      CMF+RT 
 
154 
164 
 
33 
13 
p<0.003 
 
65 
49 
p<0.006 
 
33 
50 
p<0.007 
 
46 
55 
p=0.07 
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   On the other hand, observations have 
also been reported of individual trials, 
confirmed by meta-analyses, that PMRT 
may have a deleterious effect on survival 
due to an excess of noncancer (mainly 
cardiac) deaths in irradiated patients. In a 
recent meta-analysis performed by the 
Early Breast Cancer Trialists’ Collabora-
tive Group (EBCTCG) a significant 4.3% 
increase in the risk of non-breast cancer 
deaths was found in irradiated patients 
in comparison with the control group [5]. 
However, this meta-analysis included very 
heterogenous studies with different types 
of surgical treatment and those with 
the use of outdated radiotherapy techni-
ques in which large total doses of radiation 
were delievered to the heart. In some 
of these studies large doses per fraction 
were also used, which increases the risk 
of late complications. An increased risk 
of cardiovascular mortality is probably 
caused by accelerated atherosclerosis 
in irradiated coronary arteries and may be 
a result of the suboptimal RT technique. 
In the Stockholm trial the increased 
mortality from the ischemic heart disease 
was evident only in patients treated with 
a tangential photon beams technique, 
in which a large volume of the heart was 
irradiated [6]. In the Danish studies, 
in which electron beams were used 
to treat the chest wall and parasternal 
nodes, no excess of cardiac death was 
found at 12 years of follow-up. No trend 
was revealed in the increase with time 
of the hazard rate of morbidity from 
the ischemic heart disease in relation 
to radiotherapy use [7]. In Table 3 the in-
cidence of cardiac mortality in the meta-
analysis of the “old trials” of PMRT [8] 
is presented as compared with the data 
on cardiac mortality in the “new” DBCG 
trials. 
 
Table 3. Cardiac mortality in “old” PMRT trials and cardiac mortality and morbidity in DBCG trials.  
 
No of cardiac death 
Study No of patients 
PMRT (+) PMRT (-) 
RH (95% CI), 
p value 
Meta-analysis of 6 “old” trials* 
 
DBCG 82b&82c** 
Mortality 
 
Morbidity: 
Ischemic heart disease 
 
Acute myocardial infarction 
 
3362 
 
3083 
 
99 
 
 
12 
 
 
46 
 
26 
 
67 
 
 
13 
 
 
49 
 
22 
 
1.82 ( 1.32-2.5) 
p<0.001 
 
0.84 (0.38-1.83) 
n.s. 
 
0.86(.057-1.29) 
n.s. 
1.10(0.62-1.94)  
n.s. 
 
* Trials: Manchestr Quadrate & Peripheral, Oslo I&II, Heidelberg, Stockholm (mortality for patients who survived at least 
10 years). 
** follow-up 12 years.  
 
   Therefore “the state of art” of PMRT may 
at present be summarized as follows:  
1. PMRT significantly improves the rela-
pse-free and overall survival in high 
risk breast cancer patients who also 
receive adjuvant systemic therapies, 
and  
2. PMRT may increase the risk of car-
diac deaths, but this effect may 
be avoided using modern radio-
therapy techniques. 
   However, discussion is continuing and 
divergent opinions are being formulated 
on the category of patients who really pro-
fit from PMRT and on the optimal tech-
nique (treatment volume and dose) and 
the optimal way of combining radiotherapy 
with adjuvant systemic treatment. The aim 
of this paper is to examine these 
arguments taking into account the data 
from literature and the results of own 
retrospective analysis performed in a large 
group of 1885 patients treated with 
mastectomy alone or irradiated postope-
ratively with two dose levels at the Center 
of Oncology in Krakow [9].  
A. The criticism of DBCT 82b, c and BCCA 
trials.  
   The Danish and Canadian trials have 
been criticized for several reasons:  
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a. The incidence of locoregional recur-
rences in these trials was very high 
in comparison with the experience 
of other centres, 
b. The number of axillary nodes remo-
ved during mastectomy in the Danish 
studies was low (7 on average) sug-
gesting that  surgical treatment may 
have been suboptimal and the num-
ber of involved nodes underestimated, 
c. The systemic therapies used in these 
studies were suboptimal (low dose in-
tensity CMF, tamoxifen for 1 year) 
by recent standards.  
   These objections have led to some 
doubts, particularly in US, of whether the 
results of trials which were started in the 
70s and the early 80s are relevant to the 
breast cancer patients treated today 
[10,11,12]. In this context several 
important points should be made: 
   1. The strongest risk factor in the risk 
of a locoregional failure is the number 
of metastatic axillary nodes, other factors 
include tumour size and tumour grade. 
The analysis performed at the Centre 
of Oncology in Kraków in a group of 1068 
patients treated with mastectomy alone 
showed that node involvement, tumour 
size and grade are independent risk 
factors of locoregional recurrence in a mul-
tivariate analysis. Table 4 shows the risk 
of locoregional recurrence in subgroups 
of patients with various combinations 
of these factors and demonstrates how 
the incidence of recurrences increases 
with the number and strength of risk fac-
tors [13]. In Table 5 the incidence of loco-
regional recurrences in the various clinical 
series is presented. The data were chosen 
to illustrate various issues. The results 
of the old large randomized trials confirm 
that in node positive patients treated with 
mastectomy alone long term risk of loco-
regional recurrence is in fact very high 
exceeding that seen in a control group 
of patients from the Danish and Canadian 
studies [4,14]. In more recent studies from 
the US, in which adjuvant systemic 
therapy was used, the risk was found 
to be considerably lower [15,16]. The long 
term results of the original Milan study 
reveal a low but similar risk in both: 
the CMF and control (mastectomy alone) 
group, suggesting that chemotherapy was 
not effective in reducing the risk [17]. 
There are several reasons why the inci-
dence of locoregional events is various 
in series of patients with a similar risk 
factors, e.g. in node positive patients. One 
of the causes may be the difference in the 
surgical technnique: incomplete surgery 
may result in a higher rate of locoregional 
failure. The distribution of prognostic fac-
tors may vary from population to popu-
lation, especially if the risk category is only 
broadly defined (e.g. node positive). 
The incidence of recurrence will be higher 
in a group in which most patients have 
many nodes involved in comparison with 
the group of patients majority of whom has 
a single or few metastatic lymph nodes. 
The methods of calculation of the rates 
may differ, taking into account only the first 
cause of failure or including also recurren-
ces which appeared with distant metasta-
ses or even after distant spread. The sta-
tistical methods used will also influence 
the results: crude incidence will be lower 
than actuarial cumulative incidence of re-
currence. 
 
Table 4. Survival and LRF in prognostic subgroups of patients with breast cancer treated with mastectomy alone. 
 
Prognostic subgroup No of patients 10-year overall survival (%) 
10-year LCR relapse 
(%) 
  
T1 N0 BI 
T2 N0 BI 
T2 N0 BIII 
T2 N(1-3) BI 
T2 N(1-3) BII 
T2 N≥4 BII 
T2 N≥4 BIII 
 
  30 
  80 
110 
  39 
104 
  63 
  37 
 
96 
92 
65 
73 
50 
41.5 
24 
 
  7 
  8 
23 
27 
29 
63 
70 
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Table 5. Incidence of locoregional recurrences in relation to nodal status and treatment method in breast cancer patients treated 
within various prospective studies. 
 
Study Treatment method Nodal status Locoregional recurrence rate (%) 
 
Manchester 
 
Stockholm I  
 
BCCA 
 
DBCG 82b 
 
DBCG 82c  
 
ECOG 
 
Milan 
 
 
Mastectomy alone 
 
Mastectomy alone 
 
Mastectomy + CMF 
 
Mastectomy + CMF 
 
Mastectomy + TAM 
 
Mastectomy_CMF/P/T 
 
Mastectomy alone 
Mastectomy + CMF 
 
N (-) 
N (+) 
N (-) 
N (+) 
N (1-3) 
N≥ 4 
N (1-3) 
N≥4 
N (1-3) 
N≥ 4 
N (1-3) 
N≥4 
N (+) 
N (+) 
 
16 
41.5 (10 - year) 
25 
56 (15 - year) 
33 
46 (15- year) 
30  
42     (10 - year) 
31 
46    (10- year) 
13 
29     (10 - year) 
15 
13      (20 - year) 
 
 
   2. The mean number of nodes removed 
at surgery in the Danish trials is indeed 
low and a higher incidence of axillary 
failure than in other series was observed. 
It is argued that with more adequate 
surgery the role of PMRT would become 
less important. In a recent analysis Iyer 
et al. demonstrated that the probability 
of finding a single metastatic node in axilla 
and the number of metastatic nodes 
in axilla both increase with the number 
of nodes found in the specimen and exa-
mined [18]. Thus, if only several nodes are 
removed there is a risk that the real 
number of involved axillary nodes will be 
underestimated and patient will be inclu-
ded in the node negative instead of node 
positive category or in the 1-3 node po-
sitive subgroup instead of ≥4 node po-
sitive. The small average number of nodes 
removed in the Danish trial may indeed 
lead to such underestimation to some 
extent, however there are the significant 
differences in the survival and locoregional 
failure rates between nodal subgroups 
and survival improvement was found also 
in patients in whom a higher number of no-
des (over 10) was examined. Additionally, 
in the BCCA trial, in which the average 
number of nodes was 11, locoregional 
recurrence rates and the survival benefit 
were similar to those in the DBCG trials.  
   3. The adjuvant systemic therapies used 
in the Danish and Canadian trials should 
indeed be regarded as suboptimal. 
However, data from Table 5 show that 
a full dose CMF did not reduce the inci-
dence of locoregional failure, and other 
studies have demonstrated that the ad-
dition of radiotherapy to a highly effective 
adjuvant chemotherapy lowers this inci-
dence [19,20]. Locoregional recurrences 
appeared to be the cause of failure even 
in patients who were treated with high 
dose intensive regimens, followed by BMT, 
and radiotherapy was included in treat-
ment schedules of these patients [21,22]. 
In their retrospective analysis of outcome 
of 857 patients with 10 or more positive 
lymph nodes Diab et al. found that radio-
therapy improved survival only in patients 
who received adjuvant chemotherapy [23]. 
It should be pointed out that a significant 
improvement in the disease free and o-
verall survival observed so far in clinical 
studies was found almost exclusively 
in patients who had received systemic 
therapy. Whelden et al. performed a meta-
analysis limited to 18 trials in which 
the value of PMRT was assessed in pa-
tients receiving adjuvant systemic the-
rapies. This meta-analysis also confirmed 
the improvement of survival in irradiated 
patients [24]. The above data and other 
considerations suggest that the positive 
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effect of radiotherapy on the overall sur-
vival would in fact be more pronounced 
in patients who received more effective 
systemic chemotherapy that would era-
dicate a greater proportion of subclinical 
distant metastases but would be not 
effective enough in large locoregional sub-
clinical tumours.  
 
B. Which patients should be treated with 
PMRT? 
   Patients with multiple (≥4) metastatic 
axillary nodes have the highest risk 
of locoregional recurrence, and the use 
of PMRT in this group was often re-
commended even before the survival 
benefit was proven. The use of irradiation 
in patients with few (1-3) nodes involved 
is still the subject of discussion despite 
the convincing evidence from the Danish 
and BCCA trials [25, 26]. In the US a large 
multicenter randomized trial was initiated 
to examine the value of PMRT in this sub-
group. In Table 6 absolute and propor-
tional survival benefits in the Danish and 
BCCA studies are presented. The data 
from this table strongly suggest that pa-
tients with a less advanced disease 
(1 – 3 positive lymph nodes) are more 
likely to benefit from PMRT in terms 
of survival than those with four or more 
lymph nodes involved. This hypothesis 
can be explained on the assumption that 
the number of positive nodes correlate 
with both risk of dissemination and the tu-
mour burden of micrometastatic disease. 
Thus patients with 1-3 nodes involved are 
firstly at a lower risk of distant disse-
mination, which if exists it is more likely 
to be controlled by adjuvant systemic 
therapy. Similarly, the locoregional tumour 
burden may be smaller in patients with 
1–3 than in those with >3 nodes involved 
then PMRT would be more effective 
in eradicating the subclinical disease 
in locoregional sites and thus preventing 
secondary dissemination. This is keeping 
in with the results of the meta-analysis 
published by Van de Steene et al., 
in which the survival benefit was found 
in patients with favourable crude survival 
corresponding to the patients with a sma-
ller number of involved nodes [27]. 
Table 6. Survival benefit in patients treated with PMRT within DBCG and BCCA studies, in realtion to degree of nodal 
involvement.  
 
Study Nodal involvement Absolute survival benefit 
Proportional survival 
benefit 
 
DBCG 82b* 
 
 
DBCG 82c* 
 
 
BCCA ** 
 
N+ (1-3) 
N+ ≥ 4 
 
N+ (1-3) 
N+ ≥ 4 
 
N+ (1- 3) 
N+ ≥ 4 
 
  8% 
12% 
 
11% 
  7% 
 
14% 
13% 
 
17% 
15% 
 
20% 
8.5% 
 
27% 
16% 
 
 
* benefit in overall survival  
** benefit in systemic disease free survival.  
 
C. What is the optimal technique of PMRT? 
   The discussion on the value of PMRT in-
cludes the issue of technique with respect 
of treatment volume and dose.  
   C.1. The treatment volume includes 
the chest wall and regional (axillary, sup-
raclavicular, parasternal) lymph nodes. 
The problem under discussion has been 
whether irradiaton of all these regions 
is necessary or equally important. Irra-
diation of the chest wall is not contro-
versial because the majority of the recur-
rences develop in this area, and the in-
volvement of scar and lymphatics within 
the chest wall represents an early spread 
in comparison with lymph node 
metastases and thus the risk of distant 
spread is lower. This is illustrated by 
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the data presented in Table 7. The per-
centage of recurrences occuring with 
concomitant distant metasaeses is higher 
in patients who develop nodal (supra-
calvicular) recurrence than in patients with 
chest wall recurrence. These data indicate 
that chest wall irradiation is likely to con-
tribute to survival improvement. The im-
pact of irradiation of regional nodes on su-
rvival has been less certain. There are few 
data on the relative incidence of local 
versus regional recurrences because 
in many publications local and regional 
failures are scored together. Table 8 
shows the proportions of local and regio-
nal recurrences in several series of pa-
tients treated with mastectomy alone 
or with mastectomy and systemic therapy. 
In patients treated with mastectomy alone 
regional recurrences are equally or more 
frequent than local recurrences. In patients 
receiving systemic therapies the ratio 
of local to regional recurrences seems 
to be reversed, regional recurrences still 
occurring quite frequently. 
Table 7. Proportion of local/regional recurrence with concomitant distant failure (DF) in breast cancer patients treated with 
adjuvant systemic therapy.  
 
Proportion of local/regional recurrence +DF 
Study No of patients 
Chest wall Supraclavicular 
 
DBCG 82c (2) 
(Tam alone arm) 
 
ECOG (4 trials)(15) 
 
686 
 
 
2016 
 
17/123 (14%) 
 
 
67/198 (34%) 
 
8/29 (27%) 
 
 
49/113 (43%) 
 
 
Table 8. Frequency and proportion of local and regional recurrences in node positive breast cancer patients treated 
with mastectomy alone or with mastectomy and systemic therapies.  
 
Study/treatment No of patients No of L-R recurrence % local % regional 
 
Kraków (mastectomy alone)* (9) 
 
NSABP B-04 (mastectomy alone)(28) 
 
DBCG 82c (mastectomy + TAM)(2) 
 
ECOG (4 trials:mastectomy +adjuvant 
therapy) (15)  
 
 
  483 
 
  292 
 
  686 
 
2016 
 
193 
 
  61 
 
254 
 
456 
 
42% 
 
51% 
 
53% 
 
53.5% 
 
58% 
 
49% 
 
47% 
 
46.5% 
 
 
 * retrospective analysis: 10-year actuarial LRR rates. 
 
   Irradiation of regional nodes alone was 
very popular and even overrated 
in the past, when so called “peripheral 
irradiation” was recommended in lower 
risk (1-3 positive nodes) patients. The va-
lue of this type of PMRT was studied 
in several randomized trials, e.g. in the Os-
lo II trial. An interesting point often forgot-
ten today is that in this trial adjuvant 
systemic treatment was applied in the form 
of ovarian ablation, which is an effective 
form of adjuvant therapy as demontrated 
by EBCTCG metaanalysis. In the Oslo II 
trial an improvement of survival connected 
with decreased incidence of distant meta-
stess was in fact noted, it was, however, 
offset in longer follow-up by an increased 
risk of cardiac deaths resulting from high 
dose to parasternal nodes given with 
direct photon beam with relatively high 
dose per fraction of 2.5 Gy. Nevertheless 
the results of Oslo II study indicate that 
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irradiation of regional nodes may contri-
bute to survival benefit [29,30]. One 
should also stress that in DBCG and 
BCCA trials, in which survival benefits 
were demonstrated, regional nodes had 
been treated.  
   Of all nodal areas treated in breast can-
cer patients the irradiation of internal ma-
mmary nodes has been most controversial 
[31,32,33,34,35). The arguments for and 
against are summarized in Table 9, and 
the incidence of IMN involvement from 
surgical series is presented in Table 10. 
Recently, retrospective analyses were pu-
blished in which the value of IMN irra-
diation has been negated [36]. This study, 
however, included a large proportion 
of early, mainly node negative patients, 
and only a small proportion of patients 
IMN were treated, therefore the conclu-
sions may not be relevant to high risk 
patients treated with mastectomy [37]. 
It should also be stressed that in all 
the recent randomized trials which 
demontrated survival benefit with PMRT 
the whole volume at risk, including IMN, 
was irradiated. The value of IMN irra-
diation has been the subject of clinical 
trials, especially of a large study of EORTC, 
which is still recruiting patients. Early 
results of SFRO randomized trial do not 
show survival advantage of IMN irradiation 
after mastectomy [38]. 
Table 9. Arguments for and against  irradiation of internal mammary nodes (IMN).  
 
FOR AGAINST 
 
1. High incidence of IMN involvement in surgical 
series.  
2. IMN were irradiated in trials in which survival 
benefit was demonstrated.  
3. With modern technique dose to the heart may 
be minimize.  
 
1. Very low incidence of clinical parasternal 
recurrence.  
2. Lack of the direct evidence from randomized 
trials.  
3. It complicates the technique and increases
the dose to heart.  
 
 
Table 10. Incidence of IMN involvement in relation to location of primary tumour and axillary nodes status.  
 
Localisation in breast 
Axillary nodes 
Outer Inner/central 
 
N (-) negative 
 
N (+) positive 
 
 
  5% 
 
20% 
 
10% 
 
50% 
 
   C.2. The optimal dose of PMRT is also 
an important issue, although recently 
it has been less commonly discussed. 
The dose of 45 – 50 Gy is usually recom-
mended following classical Fletcher esti-
mation which is presented in Table 11 
[39]. The recent EBCTCG meta-analysis 
showed that radiotherapy reduces the risk 
of locoregional recurrence on average by 
two thirds and did not demonstrate any 
significant difference in relation to the dose 
and technique [5]. This, however, is not 
consistent with other reports, which su-
ggest that the dose response relationship 
for the control of a sublicnical disease 
does exist in breast cancer (Table 12). 
Tables 13 and 14 show the results of ana-
lysis performed in our own material 
on the effectiveness of PMRT in preven-
ting local (chest wall) and regional (nodal) 
recurrences in relation to dose and degree 
of nodal involvement [8]. These data 
suggest that: (a) there is a dose–response 
relationship, (b) effectiveness of PMRT 
is lower in preventing chest wall failures 
than in preventing lymph node failures 
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and (c) effectiveness decreases with 
the number of positive lymph nodes 
(possibly due to a larger subclinical tumour 
burden). This observation is keeping 
in with the reports of Fletcher et al., who 
also found that 50 Gy to the chest wall 
was relatively ineffective in patients with 
massive lymph node involvement, and 
who even recommended the use of higher 
dose to that area [40,41]. In the published 
results of recent trials all local (chest wall) 
and regional (nodal) recurrences have 
been scored together and it is impossible 
to confirm whether PMRT is not equally 
effective in controlling local and nodal 
recurrences. The data from DBCG 82c 
seem to confirm that the chest wall 
disease may be more difficult to eradicate 
(73% control) than the nodal disease 
(82% control) [2]. There is also little data 
on whether the effectiveness of adjuvant 
systemic therapies is similar or different 
in both localisations. Obviously, more 
complete eradication of locoregional sub-
clinical disease with systemic therapy 
and irradiation should result in better sur-
vival preventing more effectively the se-
condary distant dissemination. With this 
respect, however, one should note that 
in BCCA trial a lower dose of 35 Gy 
resulted in a lower reduction of incidence 
of locoregional recurrence but the gain 
in survival was the same as in the Danish 
trials, in which doses of 46 – 50 Gy were 
applied [1,2,3]. The question whether 
chest wall and nodes sholud be treated 
with the same or different doses requires 
additional studies. 
 
   C.3. Since PMRT may have an adverse 
effect on survival due to an increased risk 
of cardiac deaths careful treatment 
planning is essential to minimize this risk. 
The modern PMRT techniques with 
individual CT imaging, three dimensional 
planning, with the use of electron or mixed 
beams make it possible to reduce dose 
to the heart to very low level [33,42]. 
 
Table 11. Control of subclinical nodal involvement in relation to dose. 
 
Dose (number of patients) % control 
 
30 – 35 Gy (89 pts) 
 
40 Gy (120 pts) 
 
50 Gy (273 pts) 
 
60 – 70 % 
 
80 – 90% 
 
 90% 
 
 
 
Table 12. Dose response relationship in postmastectomy radiotherapy.  
 
Study Dose Axillary nodes status Reduction in recurrence risk 
 
BCCA  
 
 
Stockholm I 
 
 
DBCG 82b  
 
 
 
DBCG 82c 
 
35 – 37 Gy 
 
 
45 Gy 
 
 
46 – 50 Gy 
 
 
 
46 – 50 Gy 
 
N+ (1-3) 
N+ ≥ 4 
 
N (-) 
N (+) 
 
N (-) 
N+ (1-3) 
N+ ≥ 4 
 
N (-) 
N+ (1-3) 
N+ ≥ 4 
 
70% 
54% 
 
80% 
66% 
 
82% 
77% 
67% 
 
74% 
81% 
76% 
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Table 13. Effectivenses of PMRT in reduction the risk of local (chest wall) recurrence in relation to the dose and involvement 
of axillary nodes.  
 
Number of nodes 
involved 
Treatemnt 
method and dose
Number 
of patients 
Local recurrence 
rate (%) 
Reduction 
in recurrence risk 
 
 
1 – 3  
 
 
≥ 4 
 
OP alone 
OP+ RT (40 Gy) 
OP+ RT (50 Gy)  
 
OP alone 
OP+ RT (40 Gy) 
OP+ RT (50Gy) 
 
265 
208 
  55 
 
173 
304 
  77 
 
15.5 
  5.7 
  3.6 
 
23 
16 
10.5 
 
 
63% 
77% 
 
 
30% 
55% 
 
 
 
Table 14. Effectiveness of PMRT in reduction the risk of regional (nodal) recurrence in relation to the dose and involvement 
of axillary nodes.  
 
Number of nodes 
involved 
Treatment 
method and dose
Number 
of patients 
Nodal recurrence 
rate (%) 
Reduction 
in recurrence risk.
 
 
(1 – 3) 
 
 
≥ 4 
 
OP alone 
OP+RT (40 Gy) 
OP+RT (50 Gy) 
 
OP alone 
OP+RT (40Gy) 
OP+RT (50Gy) 
 
265 
208 
  55 
 
173 
304 
  77 
 
 
18.8 
  7.2 
  3.6 
 
36 
18 
  5.2 
 
 
62% 
81% 
 
 
55% 
86% 
 
 
 
CONCLUSIONS 
 
1. PMRT is indicated in all node positive 
breast cancer patients.  
2. Chest wall and regional lymph nodes 
should be treated with the dose 
of 45 – 50 Gy with classical fractiona-
tion.  
3. Careful individual treatment planning 
should be used to minimize dose 
to the heart.  
4. Optimal solution of combining PMRT 
with adjuvant systemic therapies re-
quires further studies. 
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